Havemeyer Place LP Takes Position in Halozyme Therapeutics, Inc. $HALO

Havemeyer Place LP purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,576 shares of the biopharmaceutical company’s stock, valued at approximately $846,000.

Several other large investors have also made changes to their positions in HALO. DLD Asset Management LP lifted its stake in shares of Halozyme Therapeutics by 20.0% during the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after acquiring an additional 5,000,000 shares during the period. Norges Bank acquired a new position in shares of Halozyme Therapeutics during the fourth quarter valued at $128,201,000. William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics during the fourth quarter valued at $124,031,000. Voloridge Investment Management LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter valued at $77,587,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Halozyme Therapeutics during the second quarter valued at $51,295,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 1.1%

Shares of Halozyme Therapeutics stock opened at $70.73 on Tuesday. Halozyme Therapeutics, Inc. has a 1 year low of $51.06 and a 1 year high of $82.22. The business has a 50-day moving average of $66.94 and a two-hundred day moving average of $68.73. The company has a market capitalization of $8.39 billion, a P/E ratio of 25.44, a price-to-earnings-growth ratio of 0.30 and a beta of 0.88. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s revenue for the quarter was up 42.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on HALO. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. UBS Group reiterated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. HC Wainwright upped their price objective on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, Morgan Stanley dropped their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $81.60.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $51,886,572.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the transaction, the director owned 43,669 shares of the company’s stock, valued at approximately $2,891,324.49. The trade was a 3.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 93,250 shares of company stock valued at $6,299,746. 2.50% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.